弥漫大B细胞淋巴瘤一线和二线治疗真实世界数据表

数据集获取（Figshare）

• 源站标题：DataSheet_1_Real-World Estimation of First- and Second-Line Treatments for Diffuse Large B-Cell Lymphoma Using Health Insurance Data: A Belgian Population-Based Study.pdf
• DOI：10.3389/fonc.2022.824704.s001
• 发布日期：2022-02-28
• 文件数：1 个
• 文件总体积：793.11 KB
• 源站页面：https://frontiersin.figshare.com/articles/dataset/DataSheet_1_Real-World_Estimation_of_First-_and_Second-Line_Treatments_for_Diffuse_Large_B-Cell_Lymphoma_Using_Health_Insurance_Data_A_Belgian_Population-Based_Study_pdf/19246329

命令行下载

curl -L -o "DataSheet_1_Real-World Estimation of First- and Second-Line Treatments for Diffuse Large B-Cell Lymphoma Using Health Insurance Data: A Belgian Popula.pdf" "https://ndownloader.figshare.com/files/34200504"

文件清单

• DataSheet_1_Real-World Estimation of First- and Second-Line Treatments for Diffuse Large B-Cell Lymphoma Using Health Insurance Data: A Belgian Popula.pdf（793.11 KB）

文件总体积 793.11 KB（源站 API 实测）。

数据说明

We determined first- and second-line regimens, including hematopoietic stem cell transplantations, in all diffuse large B cell lymphoma (DLBCL) patients aged ≥20 yr (n = 1,888), registered at the Belgian Cancer Registry (2013–2015). Treatments were inferred from reimbursed drugs, and procedures registered in national health insurance databases. This real-world population-based study allows to assess patients usually excluded from clinical trials such as those with comorbidities, other malignancies (12%), and advanced age (28% are ≥80 yr old). Our data show that the majority of older patients are still started on first-line regimens with curative intent and a substantial proportion of them benefit from this approach. First-line treatments included full R-CHOP (44%), “incomplete” (R-)CHOP (18%), other anthracycline (14%), non-anthracycline (9%), only radiotherapy (3%), and no chemo-/radiotherapy (13%), with significant variation between age groups. The 5-year overall survival (OS) of all patients was 56% with a clear influence of age (78% [20–59 yr] versus 16% [≥85 yr]) and of the type of first-line treatments: full R-CHOP (72%), other anthracycline (58%), “incomplete” (R-)CHOP (47%), non-anthracycline (30%), only radiotherapy (30%), and no chemo-/radiotherapy (9%). Second-line therapy, presumed for refractory (7%) or relapsed disease (9%), was initiated in 252 patients (16%) and was predominantly (71%) platinum-based. The 5-year OS after second-line treatment without autologous stem cell transplantation (ASCT) was generally poor (11% in ≥70 yr versus 17% in 1 within 3 months from incidence), subsequent malignancies (HR 2.50), prior malignancies (HR 1.34), respiratory and diabetic comorbidity (HR 1.41 and 1.24), gender (HR 1.25 for males), and first-line treatment with full R-CHOP (HR 0.41) or other anthracycline-containing regimens (HR 0.72). Despite inherent limitations, patterns of care in DLBCL could be determined using an innovative approach based on Belgian health insurance data.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.3389/fonc.2022.824704.s001（source: https://frontiersin.figshare.com/articles/dataset/DataSheet_1_Real-World_Estimation_of_First-_and_Second-Line_Treatments_for_Diffuse_Large_B-Cell_Lymphoma_Using_Health_Insurance_Data_A_Belgian_Population-Based_Study_pdf/19246329）。